Dr. Massimo Cristofanilli Discusses ALK Amplification in Inflammatory Breast Cancer

Massimo Cristofanilli, MD, Chair in Medical Oncology, Director of Translational Science, Cancer Genome Institute, Fox Chase Cancer Center, discusses the investigation of small-molecule anaplastic lymphoma kinase (ALK) inhibitors to treat patients with inflammatory breast cancer (IBC).

For more information on targeted therapies, visit http://www.onclive.com/specialty/cancer-pathways